OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australie)
Inventeur(s)
Morgan, Katherine Anne
Donnelly, Paul Stephen
Wichmann, Christian Werner
Scott, Andrew Mark
Abrégé
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy. Formula (I) wherein A is selected from the group consisting of CO2R1, and PO3R1; B is selected from the group consisting of CO2R2, and PO3R2; R1, R2 and R3 are each independently selected from the group consisting of H and C1-C12alkyl; each Ra is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; each Rb is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; L is a linker having from 1 to 20 atoms in the normal chain; or a pharmaceutically acceptable salt thereof.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
2.
COPPER-CONTAINING THERAGNOSTIC COMPOUNDS AND METHODS OF USE
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a non-small cell lung cancer, small cell carcinoma of the lung, bladder cancer, colon cancer, gallbladder cancer, pancreatic cancer, esophageal cancer, melanoma, liver cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, prostate cancer, a neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a glioma, breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, and/or a metastatic cancer. The compounds include a tumor targeting domain (that includes a moiety capable of recognizing or interacting with a molecular target on the surface of tumor cells), a blood- protein binding domain, and a sarcophagine-containing domain, where the moiety of the tumor targeting domain is distal to and sterically unimpeded by the blood-protein binding domain.
A portable isolation unit for use with a bed or chair, comprising an enclosure portion configurable between a stowed state and a deployed state, in which the enclosure portion substantially shields over an end of the bed or chair; a ventilation unit configured for applying air pressure to an area beneath the enclosure portion when the enclosure portion is in the deployed state; and a portable frame to which the enclosure portion and ventilation unit are mounted.
The invention provides a rotor for a peristaltic pump, the rotor comprising a body for rotation about an axis, the body having a first side and a second side, the body supporting a plurality of spaced first rollers extending from the body on the first side, the first rollers positioned at a first common radius from the axis, the body further supporting a plurality of spaced second rollers extending from the body on the second side, the second rollers positioned at a second common radius from the axis. The invention extends to a peristaltic pumping unit comprising such a rotor assembled with a first stator and a second stator, the first stator having one or more compressible fluid channels arranged to be compressed by said first rollers and the second stator having one or more compressible fluid channels arranged to be compressed by said second rollers. The invention also concerns a stator for a peristaltic pump, having a body with a planar surface and two or more fluid channels, each fluid channel having a compressible arcuate portion on or in the planar surface of the stator, the arcuate portions arranged to be compressed by a plurality of rollers mounted on a rotor, the arcuate portions each connecting to further portions of the fluid channel extending in a direction away from the planar surface such that the fluid channels take a three dimensional path within the body of the stator.
Systems, apparatus, and methods for treating medication refractory epilepsy are disclosed. In one embodiment, a method of treating epilepsy is disclosed comprising detecting, using a first electrode array coupled to a first endovascular carrier, an electrophysiological signal of a subject. The method further comprises analyzing the electrophysiological signal using a neuromodulation unit electrically coupled to the first electrode array and stimulating an intracorporeal target of the subject using a second electrode array coupled to a second endovascular carrier implanted within a part of a bodily vessel superior to a base of the skull of the subject.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging and therapeutic agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Australie)
Inventeur(s)
Jacobe, Helen
Haites, Ruth Elizabeth
Sirisena, Sameera
Abrégé
The present disclosure relates to hydrogels composition comprising protist cells. In particular, the present disclosure relates to hydrogel compositions which may be used to encapsulate or suspend ciliated protist cells, and methods of preparing the same. The present disclosure further relates to methods of infecting molluscs with a ciliated protist cell, and methods and compositions for stabilising ciliated protist cells.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
A01N 25/34 - Formes façonnées, p.ex. feuilles, non prévues dans l'un quelconque des autres sous-groupes du présent groupe principal
The present invention generally relates to nitrification inhibitors and compositions comprising nitrification inhibitors. The present invention also relates to use of the nitrification inhibitors and compositions for application to fertilisers, plants, agricultural areas (e.g. soils or pastures) to reduce or inhibit the oxidation of ammonium nitrogen to nitrite and nitrate nitrogen, such as the oxidation of ammonia- or urea-based fertilisers.
C05G 3/90 - Mélanges d'un ou plusieurs engrais avec des additifs n'ayant pas une activité spécifique d'engrais pour influer sur la nitrification des composés d’ammonium ou de l’urée dans le sol
C05C 3/00 - Engrais contenant d'autres sels d'ammonium ou l'ammoniac lui-même, p.ex. ammoniac liquide
C05C 9/00 - Engrais contenant de l'urée ou ses composés
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
9.
METHOD OF INHIBITING OR ACTIVATING GAMMA DELTA T CELLS
OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE (Australie)
CSL INNOVATION PTY LTD (Australie)
Inventeur(s)
Behren, Andreas
Cebon, Jonathan
Cortal, Marc Rigau
Fulford, Thomas Samuel
Godfrey, Dale Ian
Hammet, Andrew
Ostrouska, Simone
Panousis, Con
Uldrich, Adam Peter
Abrégé
The present disclosure relates to methods for inhibiting activation of ?d T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?d T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
The present invention provides a method of recovering organic components from an aqueous biomass in the method comprising the steps of: (i) providing an aqueous biomass containing organic components; (ii) treatment of the aqueous biomass to release intracellular organic components from within cells of the biomass to form a biomass suspension; (ii) addition of a water-immiscible component to the biomass suspension to form a mixture comprising biomass and water-immiscible component; (iv) subjecting the mixture comprising biomass and water-immiscible component to high shear to form a water-in-water-immiscible-component emulsion; (v) separating the water-immiscible component phase from the water/aqueous phase.
The present invention relates to compositions for uses including mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by various means including dental caries, dental corrosion and fluorosis are also provided. In one aspect, the present invention provides a method of mineralizing a dental surface or sub-surface comprising contacting the dental surface or subsurface with stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP), and simultaneously or subsequently, heating the dental surface or subsurface to which the stabilized ACP and/or ACFP has been, or is being, applied to a temperature greater than 37°C. In another aspect, the present invention provides a method of mineralizing a dental surface or sub-surface comprising contacting the dental surface or subsurface with a liquid composition comprising greater than 20% w/v stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP).
The present invention relates to compositions and uses for reducing the visibility of hypomineralised dental surfaces or subsurfaces, in particular in dental enamel. In one aspect, the invention involves a method of reducing visibility of a hypomineralised dental surface or subsurface, the method comprising (i) contacting the hypomineralised dental surface or subsurface with a liquid composition comprising at least 40% w/v of phosphopeptide (PP)-stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP) at a pH of less than or equal to pH 6; and (ii) subsequently to (i), raising the pH of the liquid composition applied to the hypomineralised dental surface or subsurface to equal to, or greater than, about 9, thereby forming a gel in and/or on the hypomineralised dental surface or subsurface, thereby reducing visibility of a hypomineralised dental surface or subsurface.
A method and system for mine design utilising mathematical modelling and optimisation based on mathematical modelling of connected bubbles. A mathematical model, based on mathematical modelling of behavior of connected bubbles, is applied to the 3D block model for a mine to cluster geometric elements from the 3D block model based on physical location and properties of the physical material for each of the geometric elements, and selecting at least one set of a plurality of contiguous geometric elements for extraction based on the clustering. Each set of a plurality of contiguous blocks can be associated with a phase of a mining process.
Disclosed are assays, protocols and reagents to facilitate clinical management of pregnancy with improved pre- and post-natal health outcomes for fetuses developing in an environment of placental insufficiency.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
THE UNIVERSITY OF MELBOURNE (Australie)
Inventeur(s)
Tonkin, Chris
Uboldi, Alessandro
Mcconville, Malcolm
Blume, Martin
Abrégé
The present disclosure provides mutant parasites, in particular protozoan parasites comprising a mutation of the trehalose-6-phosphate synthase/6-phosphate phosphatase (TPS/TPP)-like gene of Toxoplasma gondii (herein referred to as 'Toxoplasma') or a homologue thereof as well as vaccines comprising same.
Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
17.
METHODS OF ASSESSING RISK OF DEVELOPING BREAST CANCER
Methods and systems for assessing the risk of a human female subject for developing breast cancer. In particular, the present disclosure relates to combining a first clinical risk assessment, a second clinical assessment based at least on breast density, and a genetic risk assessment, to obtain an improved risk analysis.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the invention and of treatment dental hypersensitivity are also provided. In one embodiment, the invention provides a stannous-associated phosphopeptide (PP) stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP) complex having a stannous ion content of equal to, or greater than, 1 mole of stannous per mole of PP but less than 4 moles of stannous per mole of PP.
The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (Australie)
Inventeur(s)
Downie, Laura Elizabeth
Yeo, Leslie
Mcdonnell, Amarin George
Abrégé
A method for evaluating Dry Eye Disease (DED) in a human or animal subject is provided. Thread thinning dynamics of a tear sample of the subject are determined using an acoustically-driven microfluidic extensional rheometry (ADMiER) instrument. At least one physical parameter value of the tear sample is calculated based at least in part on the determined thread thinning dynamics. DED is evaluated based at least in part on the at least one calculated physical parameter value of the tear sample. A device for evaluating Dry Eye Disease (DED) in a human or animal subject is also provided. The device includes an acoustically-driven microfluidic extensional rheometry (ADMiER) instrument and a processing device configured to evaluate DED based at least in part on the calculated at least one physical parameter value of the tear sample.
G01N 11/02 - Recherche des propriétés d'écoulement des matériaux, p.ex. la viscosité, la plasticité; Analyse des matériaux en déterminant les propriétés d'écoulement en mesurant l'écoulement du matériau
The present disclosure relates to methods and systems for assessing the risk of a human subject for developing colorectal cancer. These methods may be combined with the subjects clinical risk to improve risk analysis. Such methods may be used to assist decision making about appropriate colorectal cancer screening regimens.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
22.
MEDICAL DEVICE FOR SENSING AND OR STIMULATING TISSUE
Devices, methods and systems for transmitting signals through a device located in a blood vessel of an animal, for stimulating and/or sensing activity of media proximal to the device, wherein the media includes tissue and/or fluid.
A61F 2/91 - Stents ayant une forme caractérisée par des éléments filiformes; Stents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles fabriquée à partir de feuilles perforées ou de tubes perforés, p.ex. perforés par découpe au laser ou gravés
A61F 2/92 - Stents ayant la forme d’une feuille enroulée se déployant après insertion dans le vaisseau
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
Disclosed herein are Mycoplasma bovis immunogenic compositions useful in raising an immune response in animals against M. bovis. Also disclosed herein are methods for generating a protective response against infections in mammals caused by M. bovis.
A plasmonic pixel structure, comprising: a substrate; a plurality of nano-scale structures each comprising conducting and dielectric components, whereby the nano-scale structures are configured to act as nano-antennas. The nano-scale structures 5 have resonant frequencies that depend on the conducting component and sizes of the nano-scale structures. The conducting component and the sizes of the nano-scale structures are selected according to a wavelength component or components of incident light desired to be reflected or transmitted by the nano-scale structures, and the conducting component and the sizes of the nano-scale structures are selected 10 such that the nano-scale structures have respective resonant frequencies corresponding to a colour scheme.
G02F 1/23 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur pour la commande de la couleur
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
The present disclosure provides a method of forming a hermetically sealed enclosure that comprises a diamond material. The method comprises providing first and second enclosure components comprising the diamond material and having first and second recesses, respectively, at edge portions. At least one of the first and second enclosure components has a cavity. The enclosure components have respective contact surfaces at the first and second recesses and are shaped such that an outer channel is formed by the co-operation of the first and second recesses when the first and second enclosure components are contacted at the contact surfaces to form the enclosure. The method further comprises bonding a first type of material to at least surface portions of the first and second recesses of the first and second enclosure components, respectively. The method also comprises bonding a second type of material to the first type of material so that the second type of material covers at least portions of the first type of material. The second type of material is biocompatible and suitable for forming a hermetically sealed seal. In addition, the method comprises contacting the enclosure components to form the enclosure and bonding the second type of material of the first enclosure component to the second type of material of the second enclosure component so as to form a hermetically sealed seal in the outer channel.
The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
C07C 233/36 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti- calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminée; Leurs dérivés
A61P 1/02 - Préparations stomatologiques, p.ex. médicaments pour le traitement des caries, des aphtes, des périodontites
A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p.ex. dentifrices; Bains de bouche
28.
A BASE AND PHOSPHOPEPTIDE STABILIZED AMORPHOUS CALCIUM PHOSPHATE (ACP) AND/OR AMORPHOUS CALCIUM FLUORIDE PHOSPHATE (ACFP) FOR USE IN PROMOTING REMINERALISATION
The present invention relates to a base for use in promoting remineralisation of a dental surface or subsurface, whereby the base contracts the dental surface or subsurface after a phosphopeptide stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP). In particular, the base for use in promoting remineralisation of hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided.
Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p.ex. DICOM, HL7 ou PACS
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
30.
A GENE AND MUTATIONS THEREOF ASSOCIATED WITH SEIZURE AND MOVEMENT DISORDERS
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (Australie)
Inventeur(s)
Heron, Sarah Elizabeth
Dibbens, Leanne Michelle
Berkovic, Samuel Frank
Scheffer, Ingrid Eileen
Mulley, John Charles
Abrégé
The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype. Furthermore, the present invention provides kit for diagnosing or prognosing a seizure and/or movement disorder in a subject, or for identifying a subject with an increased likelihood of having an offspring predisposed to a seizure and/or movement disorder, wherein the kit includes one or more components for testing for the presence of an alteration in the PRRT2 gene in the subject.
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Parry, Laura
Conrad, Kirk
Abrégé
The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.
A61P 7/12 - Antidiurétiques, p.ex. médicaments pour le traitement du diabète insipide
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour le déclenchement de l'accouchement ou de l'avortement; Utérotoniques
33.
A TEMPERATURE SENSITIVE VACCINE STRAIN OF MYCOPLASMA HYOPNEUMONIAE AND USES THEREOF
The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.
The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM- CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
Synthesis of asymmetric bis(thiosemicarbazone) ligands typically involve stepwise reaction of the appropriate dione with a suitably functionalised thiosemicarbazide to form the mono-adduct followed by reaction of the material thus formed with another suitably functionalised thiosemicarbazide. However, the mono-adduct is rarely formed exclusively so separation of the desired product from the reaction mixture is required, reducing overall yield of the process and increasing the prospect of undesirable impurities in the final product. Additionally, the thiosemicarbazide required to provide the desired functionality in the final product is often not readily available or easy to synthesize from commercially available starting materials. The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), for example as represented by formula (l). Complexes of formula (l) can be used for the treatment of neurological conditions in which cells of the nervous system are degenerated and/or damaged as a result of neurodegenerative disorders or injuries or exposures. (see formula I)
C07C 337/08 - Composés contenant l'un des groupes p.ex. thiosemicarbazides l'autre atome d'azote étant lié de plus par une liaison double à un atome de carbone, p.ex. thiosemicarbazones
A61K 31/402 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil substitués par un groupe aryle en position 1, p.ex. pirétanide
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
C07D 207/448 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant deux atomes d'oxygène liés directement en positions 2 et 5 par une double liaison avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux autres atomes de carbone du cycle, p.ex. maléimide
C07D 215/12 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle
C07D 295/135 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de car avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (Australie)
Inventeur(s)
Dibbens, Leanne Michelle
Scheffer, Ingrid Eileen
Berkovic, Samuel Frank
Mulley, John Charles
Gecz, Jozef
Abrégé
Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH 19) protein deficiency or altered PCDH 19 protein function, in particular EFMR (Epilepsy and Mental Retardation limited to Females) are provided, as well as meth-ods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH 19 deficiency or altered PCDH 19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRN A are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A01K 67/00 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étranger; Procédés de criblage à cet effet
C12N 15/12 - Gènes codant pour des protéines animales
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
38.
COMPOSITIONS FOR DENTAL MINERALIZATION AND USES THEREOF
The present invention relates to compositions and methods for mineralizing a dental surface or subsurface including providing a composition including stabilized amorphous calcium phosphate (ACP) and a source of fluoride ions.
GRAINS RESEARCH & DEVELOPMENT CORPORATION (Australie)
ADELAIDE RESEARCH & INNOVATION PTY LTD (Australie)
THE UNIVERSITY OF MELBOURNE (Australie)
Inventeur(s)
Burton, Rachel Anita
Fincher, Geoffrey Bruce
Bacic, Antony
Abrégé
The present invention relates generally to polysaccharide synthases. More particularly, the present invention relates to (1,3;1,4)-beta-D-glucan synthases. The present invention provides, among other things, methods for influencing the level of (1,3;1,4)-beta-D-glucan produced by a cell and nucleic acid and amino acid sequences which encode (1,3;1,4)-beta-D-glucan synthases.
The present invention provides a phosphopeptide or phosphoprotein (PP) stabilised amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion greater than about 30 moles of calcium per mole of PP.
A method is provided for mineralizing a dental surface or subsurface including contacting the dental surface with a protein disrupting agent and stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP).
The present invention relates to a phosphopeptide-stabilized amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complex, wherein the complex is formed at a pH of below 7Ø Methods of making such complexes are also provided. The complexes are useful in dental applications, in particular in dental remineralisation.
brevets
